Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction

Catalina Moreno-Rabié1,2, Laurence Lapauw1,2, Hugo Gaêta-Araujo1,2,3, André Ferreira-Leite1,2,4, Wim Coucke5, Tim van den Wyngaert6,7 & Reinhilde Jacobs1,2,8*

Tooth extraction is a risk factor for the development of osteonecrosis of the jaw following treatment with antiresorptive drugs (ARDs), but not all extraction sites develop this pathology. Therefore, we aimed to identify local radiographic predictors of Medication-Related Osteonecrosis of the Jaw (MRONJ) in panoramic images of oncologic patients undergoing tooth extraction. Based on a retrospective longitudinal cohort study design, patients were included if undergoing one or more tooth extraction, with at least one administration of ARDs, and presence of pre- and post-operative panoramic radiographs. After data collection, blinded and independent observations were performed. Eleven distinct imaging-related parameters were assessed preoperatively and five postoperatively, at each extraction site. A case–control and subgroup analysis assessing MRONJ development was performed. Significance level is set to 0.05 (5%). A total of 77 oncologic patients were selected, undergoing 218 tooth extractions, from which 63 teeth (29%) in 39 patients (51%) developed MRONJ. Results showed that patients developed significantly more MRONJ with longer ARD treatment ($p = 0.057$), teeth with absent and incomplete endodontic fillings with caries, widened periodontal ligament space and/or periapical lesions ($p = 0.005$), and sclerotic and heterogenous bone patterns ($p = 0.005$). In conclusion, tooth extraction sites presenting with infections and bone sclerosis are at higher risk to develop MRONJ.

Antiresorptive drugs (ARDs) are widely used as treatment of patients with osteoporosis and cancer, among other diseases. Particularly in an oncologic setting, these drugs are used to effectively prevent skeletal morbidity in patients with metastatic bone disease or multiple myeloma, which may involve pain, nerve compression, and pathologic fractures. Despite the benefits of ARDs, a common adverse effect is Medication-Related Osteonecrosis of the Jaws (MRONJ). MRONJ corresponds to exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than eight weeks, in patients treated with antiresorptive drugs and who have not received radiation therapy to the head and neck region nor have obvious metastatic disease in the jaws. Besides the stages involving bone exposure, the American Association of Maxillofacial Surgeons (AAOMS) proposed two additional groups, namely “at risk” and stage 0. Whereas both refer to the absence of bone exposure, the first includes asymptomatic patients receiving ARD and the second one involves patients presenting with non-specific symptoms or clinical and radiographic findings.

Within the systemic risk factors associated to MRONJ development are the type and dose of these medications, but most importantly their cumulative dosage, in particular the higher doses administered for longer periods. Some examples of bisphosphonates are zoledronic acid, alendronate, ibandronate, pamidronate, and risedronate. Other implicated drugs include monoclonal antibodies such as denosumab, which, like bisphosphonates, alter the bone resorption-apposition balance to prevent skeletal-related events.

Tooth extractions are often reported as an important triggering factor for this pathology. Though, experts suggest that underlying infections at the extraction site, such as periodontitis or periapical lesions, could play an

---

1OMFS-IMPATH Research Group, Department of Imaging and Pathology, Faculty of Medicine, University of Leuven, Leuven, Belgium. 2Department of Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium. 3Oral Radiology Area, School of Dentistry, Federal University of Alfenas, Alfenas, Brazil. 4Department of Dentistry, Faculty of Health Sciences, University of Brasilia, Brasilia, Brazil. 5Certified Freelance Statistician, Edegem, Belgium. 6Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium. 7Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 8Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden. *email: reinhilde.jacobs@ki.se
even greater role in the onset of MRONJ\textsuperscript{7,10}, especially when analyzing patients who had multiple tooth extractions and in whom only some of these sites developed osteonecrosis\textsuperscript{11}, thus having the same systemic condition, but different local factors. Perhaps these sites could be masking an unexposed form of the pathology that would only be revealed at the time of extraction\textsuperscript{7}, presenting in their radiographic appearance, sclerosis, thickening of the lamina dura, and persistence of the extraction socket\textsuperscript{12}. In these cases, a radiographic evaluation is of great value to identify hidden lesions or abnormal bone patterns and recognize the high-risk sites for MRONJ.

Bearing the previous evidence in mind, the main objective of this study was to identify local radiographic characteristics in panoramic images that act as a risk factor for development of MRONJ in oncologic patients currently taking or with a history of antiresorptive drugs undergoing tooth extractions.

Material and methods
Study design and settings. Prior to the start of this study, ethical approval was granted by the ethical committee of UZ/KU Leuven (S63934) and waived the need for informed consent. This study corresponds to a retrospective longitudinal cohort study, and to report the present information, the STROBE guidelines were followed\textsuperscript{13}. In addition, ethical standards from the Institutional Review Board and the Helsinki Declaration were obeyed.

Participant selection. A retrospective search was carried out in the database of University Hospitals Leuven, where medical files of patients in treatment with ARD, who visited the Oral and Maxillofacial Surgery department between January 1st, 2010, and December 30th, 2019, were assessed. The inclusion criteria included, (1) patients in the category “at risk” according to the AAOMS\textsuperscript{6}, (2) at least one administration of ARD in oncologic doses, (3) had undergone one or more tooth extractions, (4) had a pre- and post-operative panoramic image, and (5) documented follow-up until mucosal healing within eight weeks to refute or exposed bone for at least eight weeks to confirm the clinical development of MRONJ. Exclusion criteria were, (1) history of radiation in the head and the neck region, (2) prior MRONJ diagnosis, (3) insufficient image quality (i.e., artefacts) and/or objects in the extraction site (i.e. implants), (4) pre-operative radiographs acquired earlier than one year prior to tooth extraction, and (5) concomitant maxillofacial pathologies.

After including the study group, a control group of patients who were age-, gender-, tooth-, and sextant of extraction matched was selected from the same database. Inclusion criteria for the control group were, no intake of ARD and having panoramic radiographs from before and after a tooth extraction. Further exclusion criteria were as mentioned for the study patients.

Data selection. Along with the panoramic images, clinical information was collected from the patient’s files. The following variables were included: age, gender, tobacco and alcohol use, oncologic diagnosis, previous chemotherapy and/or radiotherapy to other body regions than to the head and neck, antiresorptive drug, dosage, treatment duration, corticosteroids intake, date of the tooth extraction(s), number, site and extracted tooth, date of chemotherapy and/or radiotherapy to other body regions than to the head and neck, antiresorptive drug, dosage, date of ARD administration, type of ARD (e.g., bisphosphonate or denosumab), and date of ARD discontinuation. Furthermore, clinical files were reviewed to determine the date of the tooth extraction(s), the number of teeth extracted, and the site of extraction. Antiresorptive drug dosage was recorded as mg/day, and the duration of ARD administration was determined as months.

Radiographic assessment. Panoramic radiographs were acquired using VistaPano S or S Ceph (Dürr Dental SE, Bietigheim-Bissingen, Germany) at 73 kVp, 12 mA, and an exposure time of 7 s. Images of eligible study and control participants were anonymized, exported in DICOM format, and assigned an arbitrary participant number. All images were then transformed to TIFF files, and observations were done using ImageJ program version 1.53j (Wayne Rasband, https://imagej.nih.gov/ij/). Blinded and independent observations were performed by two dentomaxillofacial radiologists and a general dentist. Prior to the radiographic assessment, a calibration session was held to assess 20 panoramic images from ten before and after tooth extraction cases external to this study, to achieve baseline consensus in the diagnosis. The observations took place in a room with dim light, using a high-resolution display (MD Barco MDRC-2221; Barco, Kortrijk, Belgium) at approximately 60 cm. After evaluation, the result of the observation was calculated using the mode. For example, if two observers judged a parameter as present and one as absent, then it was considered as present. If the mode could not be applied because three different interpretations were assigned, the case was discussed individually until agreement was reached. One month after the first assessment, a second reading session was carried out with 10% of the sample to evaluate the intraobserver agreement. The following parameters were assessed in the panoramic radiographs before the extraction at a tooth level, based on the description of Gaêta-Araujo et al.\textsuperscript{11}:

1. Horizontal bone loss: absent/initial bone loss, if bone resorption was up to 1/3 cervical of the root, or moderate/severe bone loss, if bone resorption was more than 1/3 cervical of the root.
2. Angular bone loss: absent or present.
3. Fucation involvement: absent or present.
4. Periodontal ligament space: normal or widened.
5. Lamina dura: normal or thickened.
6. Root remnant: absent or present.
7. Periapical lesion: absent or present.
8. Endodontic treatment: absent, adequate endodontic filling in length or width, or inadequate endodontic filling (over and underfilling).
9. Prosthodontics: absence or presence of crowns, bridges, and/or fillings.
10. Caries: absent, dentin caries, or caries in contact with or overlapping the pulp cavity.
11. Bone pattern surrounding the tooth: normal, sclerotic (increased radiopacity), radiolucent, or heterogeneous (mixed radiolucent and radiopaque).

Furthermore, parameters appraised in the extraction site on the respective post-operative panoramic image included:

1. Bone pattern: as described before.
2. Alveolar socket: not visible or visible.
3. Lamina dura: not visible or visible.
4. Sequestrum formation: absent or present.
5. Crater-like defect: with reference to an accentuated resorption in the form of a prominent concavity, absent or present.

Statistical analysis. The statistical analysis was done using RStudio Software version 4.0.4 (RStudio, Boston, MA US). A p-value ≤ 0.05 was considered statistically significant. Fleiss’ Kappa test was used to calculate interobserver agreement and Cohen’s Kappa test for intraobserver agreement. Agreement was considered fair when the test result was > 0.21–0.40, moderate when > 0.41–0.60, substantial when > 0.61–0.80, and almost perfect when > 0.81–0.99

Univariate analysis. The significance of differences in characteristics between control and study patients was tested before the start of the analysis for gender, age, and extracted tooth, using Chi-Square and Wilcoxon rank-sum test.

Observations and clinical data documented for each extracted tooth were tested for independency using the Chi-square/Fisher’s exact test and the Wilcoxon rank-sum test for ordinal variables. Comparisons were made between the control and antiresorptive-treated group. In addition, the latter was divided into sites that developed MRONJ (MRONJ+) after tooth extraction and sites that did not (MRONJ−). The null hypothesis was that the assessed parameters are independent in the control and study group, and in the MRONJ+ and MRONJ− extraction sites. Lastly, the McNemar-Bowker test was used to compare pre- and post-operative appearance of bone pattern.

Considering that some patients had multiple tooth extractions, with some sites MRONJ+ and other sites MRONJ−, further analysis was carried out using a generalized linear mixed model, which tested the independency of the assessed variables while respecting the grouped character of the data.

Multivariate analysis of risk factors. A stepwise model selection was performed, through a generalized linear model for binary data using the logit link and with patient as random factor, to identify the combination of variables that had the best relationship with MRONJ development among the study group. The assessed variables were horizontal bone loss, angular bone defect, furcation involvement, periodontal ligament, lamina dura, root remnant, periapical lesion, endodontic treatment, presence of composite or crown, presence of caries, pre-operative bone pattern, type of extracted tooth, sextant, duration of ARD treatment, and presence of drug holiday.

For those variables that were part of the selected model, a pairwise comparison between the group’s variables was performed and corrected for simultaneous hypothesis testing according to Tukey.

Results
In this ten-year observational study, 1468 patients visited the Oral and Maxillofacial Surgery department and were currently or in the past treated with ARDs. From these patients, 927 had either prior diagnosis of MRONJ or only one panoramic image available, 219 patients did not have tooth extraction, 130 received ARD treatment for other reasons than oncology, 89 did not have either a pre- or post-operative panoramic image, 22 had images with bad quality, and 4 had panoramic images older than one year before their tooth extraction.

From the total, 77 patients, who underwent 218 tooth extractions complied with the inclusion criteria, and 88 patients with 238 tooth extractions were selected as controls. The study and control group showed no significant differences regarding age (W = 3392, p = 0.992), gender (X² = 0.0185, p = 0.892), tooth (W = 26,859, p = 0.514), sextant (W = 25,718, p = 0.872), and number of extractions (W = 3293, p = 0.739). Demographic data can be found in Table 1, at a patient level, and in Table 2, at a tooth level.

All included patients had at least one administration of zoledronic acid 4 mg or denosumab 120 mg. Eleven patients had treatment with a combination of a bisphosphonate and denosumab. The mean duration of the ARD treatment was 20.8 months (range 1–83). The mean time between pre-operative panoramic radiograph and tooth extraction was of 1.6 months (range 0–12) for the oncologic group and 1.1 months (range 0–9.6) for the control group. While the mean time interval between tooth extraction and post-operative panoramic was 9.6 months (range 0–61.2) for the study and 7.3 months (range 0–70.8) for the control group.

From the 77 oncologic patients, 39 developed MRONJ in 63 tooth extraction sites (50.6% of the study group, 95% CI 0.47–0.70; 28.9% of the extracted teeth, 95% CI 0.23–0.35). From the affected patients, 21 had from one to three tooth extractions and developed MRONJ in all sites, while 18 patients had in average 5.6 tooth extractions (range 2–24) and presented both MRONJ+ and MRONJ− sites. This last group had in average two MRONJ+ sites (range 1–8).

Observations and clinical data documented for each extracted tooth were tested for independency using the Chi-Square and Wilcoxon rank-sum test.

Univariate analysis. The significance of differences in characteristics between control and study patients was tested before the start of the analysis for gender, age, and extracted tooth, using Chi-Square and Wilcoxon rank-sum test.

Observations and clinical data documented for each extracted tooth were tested for independency using the Chi-square/Fisher’s exact test and the Wilcoxon rank-sum test for ordinal variables. Comparisons were made between the control and antiresorptive-treated group. In addition, the latter was divided into sites that developed MRONJ (MRONJ+) after tooth extraction and sites that did not (MRONJ−). The null hypothesis was that the assessed parameters are independent in the control and study group, and in the MRONJ+ and MRONJ− extraction sites. Lastly, the McNemar-Bowker test was used to compare pre- and post-operative appearance of bone pattern.

Considering that some patients had multiple tooth extractions, with some sites MRONJ+ and other sites MRONJ−, further analysis was carried out using a generalized linear mixed model, which tested the independency of the assessed variables while respecting the grouped character of the data.

Multivariate analysis of risk factors. A stepwise model selection was performed, through a generalized linear model for binary data using the logit link and with patient as random factor, to identify the combination of variables that had the best relationship with MRONJ development among the study group. The assessed variables were horizontal bone loss, angular bone defect, furcation involvement, periodontal ligament, lamina dura, root remnant, periapical lesion, endodontic treatment, presence of composite or crown, presence of caries, pre-operative bone pattern, type of extracted tooth, sextant, duration of ARD treatment, and presence of drug holiday.

For those variables that were part of the selected model, a pairwise comparison between the group’s variables was performed and corrected for simultaneous hypothesis testing according to Tukey.
| Characteristics                                      | Oncologic group | Control |
|------------------------------------------------------|-----------------|---------|
| Number of patients, n                                | 77              | 88      |
| Development of osteonecrosis, n                      | MRONJ+ %        | MRONJ− %|
|                                                     | 39              | 38      |
| Age (years)                                          |                 |         |
| 30–45                                               | 1               | 50%     |
|                                                     | 1               | 50%     |
|                                                     | 3               |         |
| 46–60                                               | 11              | 52%     |
|                                                     | 10              | 48%     |
|                                                     | 22              |         |
| 61–75                                               | 12              | 40%     |
|                                                     | 18              | 60%     |
|                                                     | 43              |         |
| 76–92                                               | 15              | 63%     |
|                                                     | 9               | 38%     |
|                                                     | 20              |         |
| Age a tooth extraction (mean ± SD)                  | 68.4 ± 11.3     | 67.2 ± 10.9 |
|                                                     | 67.9 ± 11.2     |         |
| Sex, n                                               |                 |         |
| Female                                               | 19              | 45%     |
|                                                     | 23              | 55%     |
|                                                     | 50              |         |
| Male                                                 | 20              | 57%     |
|                                                     | 15              | 43%     |
|                                                     | 38              |         |
| Underlying disease, n                                |                 |         |
| Breast cancer                                        | 17              | 49%     |
|                                                     | 18              | 51%     |
|                                                     | NA              |         |
| Prostate cancer                                      | 9               | 60%     |
|                                                     | 6               | 40%     |
|                                                     | NA              |         |
| Multiple myeloma                                     | 6               | 33%     |
|                                                     | 12              | 67%     |
|                                                     | NA              |         |
| Lung cancer                                          | 3               | 60%     |
|                                                     | 2               | 40%     |
|                                                     | NA              |         |
| Gastrointestinal cancer                              | 1               | 100%    |
|                                                     | 0               | 0%      |
|                                                     | NA              |         |
| Renal cancer                                         | 3               | 100%    |
|                                                     | 0               | 0%      |
|                                                     | NA              |         |
| Chemo- and radiotherapy, n                           |                 |         |
| None                                                 | 4               | 50%     |
|                                                     | 4               | 50%     |
|                                                     | NA              |         |
| Chemotherapy                                         | 6               | 67%     |
|                                                     | 3               | 33%     |
|                                                     | NA              |         |
| Radiotherapy                                         | 7               | 58%     |
|                                                     | 5               | 42%     |
|                                                     | NA              |         |
| Both                                                 | 22              | 46%     |
|                                                     | 26              | 54%     |
|                                                     | NA              |         |
| Antiresorptive drug, n                               |                 |         |
| Bisphosphonate                                       | 12              | 41%     |
|                                                     | 17              | 59%     |
|                                                     | NA              |         |
| Denosumab                                            | 19              | 51%     |
|                                                     | 18              | 49%     |
|                                                     | NA              |         |
| Both                                                 | 8               | 73%     |
|                                                     | 3               | 27%     |
|                                                     | NA              |         |
| Number of ARDs, n                                    |                 |         |
| 1                                                    | 31              | 48%     |
|                                                     | 33              | 52%     |
|                                                     | NA              |         |
| 2                                                    | 7               | 58%     |
|                                                     | 5               | 42%     |
|                                                     | NA              |         |
| 3                                                    | 1               | 100%    |
|                                                     | 0               | 0%      |
|                                                     | NA              |         |
| Time on ARDs (months), n (%                          |                 |         |
| ≤ 12                                                 | 12              | 41%     |
|                                                     | 17              | 59%     |
|                                                     | NA              |         |
| > 12–≤24                                            | 10              | 40%     |
|                                                     | 15              | 60%     |
|                                                     | NA              |         |
| > 24–≤36                                            | 11              | 79%     |
|                                                     | 3               | 21%     |
|                                                     | NA              |         |
| > 36–≤48                                            | 1               | 33%     |
|                                                     | 2               | 67%     |
|                                                     | NA              |         |
| > 48–≤60                                            | 4               | 80%     |
|                                                     | 1               | 20%     |
|                                                     | NA              |         |
| > 60–≤120                                           | 1               | 100%    |
|                                                     | 0               | 0%      |
|                                                     | NA              |         |
| Corticoid use, n                                     |                 |         |
| No                                                   | 25              | 56%     |
|                                                     | 20              | 44%     |
|                                                     | 78              |         |
| Yes                                                  | 14              | 44%     |
|                                                     | 18              | 56%     |
|                                                     | 10              |         |
| Alcohol consumption, n                               |                 |         |
| No consumption                                       | 14              | 54%     |
|                                                     | 12              | 46%     |
|                                                     | 30              |         |
| 1–2 units daily                                      | 15              | 45%     |
|                                                     | 18              | 55%     |
|                                                     | 38              |         |
| > 2 units daily                                      | 0               | 0%      |
|                                                     | 1               | 100%    |
|                                                     | 6               |         |
| Unknown                                              | 10              | 59%     |
|                                                     | 7               | 41%     |
|                                                     | 14              |         |
| Tobacco use, n                                       |                 |         |
| Previous user                                        | 13              | 68%     |
|                                                     | 6               | 32%     |
|                                                     | 28              |         |
| Active user                                          | 6               | 67%     |
|                                                     | 3               | 33%     |
|                                                     | 5               |         |
| Non-user                                             | 16              | 41%     |
|                                                     | 23               | 59%     |
|                                                     | 52              |         |
| Unknown                                              | 4               | 40%     |
|                                                     | 6               | 60%     |
|                                                     | 3               |         |

Table 1. Descriptive data from study group and control patients. NA, not applicable.
Among the antiresorptive-treated patients, MRONJ+ patients had a longer treatment duration with a mean of 24.9 months, than MRONJ− patients, who had a mean of 16.7 months. Despite this difference, the test result was borderline significant ($W = 555$, $p = 0.057$). Furthermore, no significant differences were found in the distribution of age ($W = 785$, $p = 0.659$), gender ($X^2 = 0.659$, $p = 0.417$), history of chemotherapy and/or radiotherapy ($p = 0.679$), type and number of ARDs ($X^2 = 3.149$, $p = 0.207$; $W = 684$, $p = 0.376$), duration of corticosteroid use ($X^2 = 0.624$, $p = 0.429$), alcohol consumption ($W = 500$, $p = 0.394$), and tobacco abuse ($p = 0.115$), between those who did and did not develop the pathology.

Regarding the extracted teeth, no significant differences were observed in the type of extracted tooth ($W = 4695$, $p = 0.633$), region ($W = 4866$, $p = 0.969$), presence of drug holiday ($X^2 = 3.149$, $p = 0.207$; $W = 684$, $p = 0.376$), duration of corticosteroid use ($X^2 = 0.624$, $p = 0.429$), alcohol consumption ($W = 500$, $p = 0.394$), and tobacco abuse ($p = 0.115$), between those who did and did not develop the pathology.

The overall Kappa for interobserver agreement was moderate (0.66), ranging between a fair (0.34) and an almost perfect agreement (0.96) in the periodontal ligament assessment and the presence of endodontic treatment, respectively. The mean Kappa value for the intraobserver agreement was substantial (0.79) for the overall assessment, ranging between a moderate agreement (0.45) in the assessment of lamina dura, and an almost perfect agreement (0.98) in the presence of endodontic treatment.

### Table 2. Descriptive data of the extracted teeth in the study and control group. Further description of the teeth from the study group that did (MRONJ+) and did not (MRONJ−) develop osteonecrosis is given.

| Characteristics | Oncologic group | Control |
|-----------------|----------------|---------|
| Number of extracted teeth, n | 218 | 238 |
| Development of osteonecrosis, n (%) | MRONJ+ | % | MRONJ− | % | NA |
| | 63 | 29% | 155 | 71% | |
| Type of teeth, n (%) | | | | | |
| Incisors and canines | 18 | 30% | 43 | 70% | 75 |
| Premolars | 14 | 24% | 45 | 76% | 59 |
| Molars | 31 | 32% | 67 | 68% | 104 |
| Region, n (%) | | | | | |
| Anterior maxilla | 8 | 27% | 22 | 73% | 34 |
| Posterior maxilla | 22 | 26% | 63 | 74% | 87 |
| Anterior mandible | 10 | 32% | 21 | 68% | 41 |
| Posterior mandible | 23 | 32% | 49 | 68% | 76 |
| Underlying dental disease, n (%)* | | | | | |
| Nonapparent | 3 | 12% | 21 | 88% | 23 |
| Periodontal disease | 3 | 20% | 12 | 80% | 31 |
| Endodontic pathology | 17 | 31% | 38 | 69% | 62 |
| Combined lesion | 40 | 32% | 84 | 68% | 122 |
| Drug holiday >60 days, n (%) | | | | | |
| No | 20 | 36% | 35 | 64% | NA |
| Yes | 43 | 26% | 120 | 74% | |
| Antibiotic prophylaxis, n (%) | | | | | |
| No | 4 | 50% | 4 | 50% | 225 |
| Yes | 59 | 29% | 146 | 71% | 13 |
| Antiseptic mouthwash, n (%) | | | | | |
| No | 2 | 40% | 3 | 60% | 9 |
| Yes | 61 | 29% | 147 | 71% | 229 |
| Use of L-PRF, n (%) | | | | | |
| No | 18 | 38% | 29 | 62% | 228 |
| Yes | 45 | 27% | 122 | 73% | 10 |
| MRONJ worse stage, n (%) | | | | | |
| Stage 1 | 32 | 51% | NA | NA | |
| Stage 2 | 28 | 44% | NA | NA | |
| Stage 3 | 3 | 5% | NA | NA | |
Pre- and post-operative parameters: control versus study group. Thickening of the lamina dura was significantly more present in the antiresorptive-treated patients (10%) than in the control group (3%, \(p = 0.003\)). Significant lower caries and specifically pulpal caries prevalence was also seen in this group (34%) in comparison to the control group (45%, \(p = 0.006\)).

When looking at the bone pattern surrounding the extraction site postoperatively, the oncologic group had a higher prevalence of a sclerotic (33%) and a heterogeneous pattern (6%, \(p < 0.001\)), than the control group (20% and 0%, respectively). The visibility of the alveolar socket after the extraction (\(p < 0.001\)), and when looking at those sites with images taken at least one year postoperatively (\(p < 0.001\)), were also significantly more prevalent among the patients under ARD. The same was observed for the persistence of the lamina dura (\(p < 0.001\)). Finally, the visibility of sequestrum was present only in the ARD group (3%, \(p = 0.012\)).

Pre- and post-operative parameters: MRONJ+ versus MRONJ−. Teeth that were not treated endodontically developed MRONJ more frequently (35%), than teeth with endodontic treatments (17%). However, when present, an endodontic filling material insufficient in length and/ or width increased the chance of the onset of MRONJ (\(p = 0.005\)). Additionally, 82% of the extracted teeth had either caries, widened periodontal ligament space and/or periapical lesions. From these decayed teeth, 37% without endodontic treatment, 13% with adequate fillings, and 31% with inadequate fillings, developed MRONJ. There was no development of MRONJ in teeth without signs of endodontic infection and presence of endodontic treatment, whether adequate or inadequate. Lastly, a pre-operative bone pattern different than normal increased the likelihood of MRONJ (\(p = 0.005\)), as 46% of the sclerotic and 67% of the heterogeneous sites developed the pathology. Detailed results are displayed in Table 3 and an illustrative example in Fig. 1.

A post-operative heterogeneous (83%) and radiolucent bone pattern (67%) was witnessed significantly more at MRONJ+ than MRONJ− sites (\(p < 0.001\)), while 67% of the sclerotic and 79% of the normal bone patterns were seen in MRONJ− sites. Furthermore, sequestrum formation was exclusively seen in locations that developed MRONJ. These differences were thus significant (\(p < 0.001\)). Moreover, crater-like defects were significantly more detected, and when present more extensive, in MRONJ+ sites (62%) in comparison to MRONJ− (< 0.001).

Results of the paired test regarding the bone pattern before and after tooth extraction show a significant difference in the appearance among the oncologic patients (\(X^2 = 36.77, df = 6, p < 0.001\)) but not in the control group (\(X^2 = 3.27, df = 6, p = 0.773\)). In the study group, it was seen that 38 sites that had initially a normal trabecular pattern showed a sclerotic one after surgery, and four a heterogenous pattern. Moreover, eight sites with a pre-operative sclerotic pattern showed after tooth extraction a heterogeneous one.

Lastly, teeth were classified based on their radiographic characteristics into, periodontally diseased, with endodontic pathology, with endodontic-periodontal combined lesions, or no apparent disease, as described in Table 2. However, no significant differences were found between the control and study group (\(p = 0.161\)) nor the subgroups MRONJ+ and MRONJ− (\(p = 0.219\)).

Within patient analysis: MRONJ+ and MRONJ−. When looking at ARD-patients that had multiple extractions and sites that did and did not develop MRONJ, the assessment of endodontic treatment status (\(p = 0.033\)) and pre-operative surrounding bone pattern (\(p < 0.001\)) showed significant results. More specifically, and as mentioned before, a sclerotic bone pattern and absent and inadequate endodontic treatments showed a higher predisposition for the pathology.

Multivariate analysis of risk factors. Additionally, the logistic regression model showed significant results in the pre-operative assessment for the variables, endodontic treatment (\(p = 0.019\)), periapical lesion (\(p = 0.002\)), surrounding bone pattern (\(p = 0.013\)), and angular bone defect (\(p = 0.048\)). However, when performing pairwise comparisons and correcting for multiple testing, only the absence of periapical lesion (\(OR = 1.78, 95\% CI 1.459–2.175, p = 0.002\)) and angular bone defect (\(OR = 1.72, 95\% CI 1.278–2.306, p = 0.048\)), and the presence of a sclerotic bone pattern (\(OR = 3.45, 95\% CI 1.094–10.309, p = 0.027\)), showed significant results (Fig. 2).

Discussion
Radiographic bone changes in the maxilla and mandible, after the intake of antiresorptive drugs, have been widely reported in the literature even before clinical exposure of bone in the oral cavity. Although, it is unclear whether most of these findings are solely related to the antiresorptive therapy, indicate a potential progress to osteonecrosis, or represent different stages of the necrotic process15. In the present study, we aimed to confirm the associations we previously identified in a smaller and different patient cohort, and validate those pre-operative radiologic local risk factors to the development of MRONJ in patients treated with oncologic-related doses undergoing tooth extraction11. To our knowledge, this is the first large series to include a pre- and post-operative radiologic assessment of the extraction site.

Prevention in patients who belong to the category “at risk” according the AAOMS6 is key to reduce the incidence of this pathology36–18. Yet, these strategies are not always timely and dental extractions may become inevitable. Given the need for extractions, it is worth questioning how many of these teeth with pain, associated radiographic changes and absence of bone exposure are classified as “at risk”, when in fact they belong to “stage 0”. This refers above all to sites that showed clinical post-operative bone exposure and suggests that the pain, initially considered of dental origin, might be due to an undiagnosed osteonecrosis. Validating this point, Nico-latou-Galitis et al. found in such patients the presence of necrotic bone in biopsies obtained at tooth extraction10.
and risk assessment. However, for a thorough diagnosis, a three-dimensional method such as computed tomography (CT) and Cone Beam CT is recommended. These tools allow the assessment of the extension of the pathology and to identify incipient lesions like those seen in patients “at risk” or in “stage 0”. Consequently, new diagnostic staging systems have been proposed using a complement of clinical and radiographic signs.

Table 3. Shows the distribution of extraction sites according to pre- and post-operative radiographic characteristics observed in the MRONJ+ and MRONJ− subgroups and in the control group. The p-value under “oncologic group” describe the results obtained from the comparison of MRONJ+ and MRONJ− sites, while the p-value under “control group” describe the results from the comparison of study and control sites. Italic text is marked in those assessments where differences are statistically significant. Results obtained using the exact chi-square/Fisher’s exact test, except for (*), which used the Wilcoxon rank sum test.

![Table 3](https://www.nature.com/scientificreports/)

and risk assessment. However, for a thorough diagnosis, a three-dimensional method such as computed tomography (CT) and Cone Beam CT is recommended. These tools allow the assessment of the extension of the pathology and to identify incipient lesions like those seen in patients “at risk” or in “stage 0”. Consequently, new diagnostic staging systems have been proposed using a complement of clinical and radiographic signs.

Comparable to what has been described in other studies, patients under ARD, in contrast to the control group, showed significantly more thickening of the lamina dura. Thickening of the lamina dura and the mandibular cortex, enhancement of the mandibular canal, and trabecular sclerosis are all examples of the sclerosing process that the bone undergoes secondary to antiresorptive treatment. These sclerotic forms have been
Figure 1. Cropped panoramic images showing pre-operative sites (a–c) and their respective post-operative evolution (d–f). Pre-operative images show presence of risk factors, teeth without endodontic treatment and with periapical lesion (a, c), incomplete endodontic filling in length and presence of caries (b), and sclerotic bone pattern (b, c; white arrow). All extraction sites developed osteonecrosis, showing a heterogeneous bone pattern (d, f), a sclerotic bone pattern (e), visible extraction socket (e, f), persistence of the lamina dura (f; white arrow), and sequester formation (f).

Figure 2. Cropped panoramic radiographs of a 67-year-old female in treatment with denosumab, showing tooth 43 two months before extraction (a), and ten (b) and eighteen months after (c). This site had absence of periapical lesion and angular bone defect, but presence of sclerosis and widening of the periodontal ligament space. Osteonecrosis was diagnosed eight weeks after surgery, as the site did not heal. Persistence of the alveolar socket and sclerotic pattern can be seen postoperatively.
reported by numerous authors. In fact, Gaêta-Araújo et al. argued that such sclerotic changes in bone might have a better relationship with the anti-resorptive therapy per se than a predisposing factor for MRONJ. In the present sample, sites which initially showed sclerosis seem to have a larger chance of developing osteonecrosis than those with a normal pattern. Besides, bone remodeling led in eight initially sclerotic sites to a postoperative heterogeneous pattern, which in most cases (7/8) were associated to MRONJ, while bone remodeling from a normal to a heterogeneous pattern was less common. Albeit every extracted tooth in sclerotic sites had either periodontal, endodontic, or endodontic-periodontal disease. As discussed by other authors, these sclerotic changes can also be a bony response to local dental infection. Thus, it is conceivable that sites with sclerotic changes represent a risk factor for MRONJ, but this higher risk could be also due to underlying dental disease, or a combination of both.

Although the results border on significance, oncologic patients with longer ARD treatments and undergoing tooth extractions have a higher chance of developing osteonecrosis, since MRONJ+ patients had a mean treatment of 24 months and MRONJ− of 16 months. These findings align to what is reported in the literature. Some authors debate that besides the length of the treatment, the type of drug, whether bisphosphonates or denosumab, differed in their radiographic appearance. However, these findings are described in exposed variants of MRONJ and these differences were not studied in this cohort due to the restricted sample size.

Perhaps the most important findings of the present study are those related to the MRONJ+ group, being that the pathology presented itself significantly more in teeth with absent and incomplete endodontic fillings, and a sclerotic and heterogeneous alveolar bone pattern. Furthermore, the most likely combination of radiographic characteristics leading to MRONJ was a preoperative sclerotic bone pattern in absence of periapical lesion and angular bone defect. Nevertheless, teeth with these features were not exempt of dental disease, as they had periodontal ligament space widening (79%), radiographic signs of periodontitis (62%), caries (50%), or were root remnants (29%). Therefore, the results of the multivariate analysis may find an explanation in the sample distribution, rather than in the absence of chronic infection and its relationship with MRONJ.

Endodontic treatments have been strongly advocated in patients receiving ARD since the first appearances of osteonecrosis, which in turn is associated with previous bone sclerosis at the site. In addition, osteolytic changes are associated with progression to exposed osteonecrosis and sequestrum formation. In our sample, a heterogeneous bone pattern, sequestrum formation, persistence of the alveolar socket, and crater-like defect were seen significantly more in the MRONJ+ group. Still, sequestrum appears to be a pathognomonic feature of MRONJ, as it appeared only in MRONJ+ sites. Though, knowing that this pathology manifests itself early with different bone patterns and absence of clinically exposed bone, it may be that some of these findings are a subclinical form of osteonecrosis. This observation stresses the value of diagnostic imaging and a closer follow-up.

Among the limitations of this study, we found those inherent to its retrospective nature, namely, lack of data recording in the patient file, surgical variability, different ARD treatment and drug holiday duration, polypharmacy and comorbidity factors, midst other variables that could not be fully controlled. In addition, the prevalence of MRONJ in this sample, 51% of the patients and 29% of the extracted teeth, seems higher than what is reported in the literature (0.5–4.6% of the patients), but comparable to a prior Belgian study, where the risk of MRONJ increased to 20% after tooth extractions. Lastly, the timing of the exposure to the radiograph before and after the extraction was not homogeneous either, giving room for changes in the appearance of the assessment perceptible to the observer.

The clinical relevance of this study relies on the need for diagnostic imaging prior to tooth extraction in oncologic patients under ARD. Specially to identify a sclerotic and heterogeneous preoperative bone pattern, which in this study we consider as high risk for MRONJ, but perhaps they are already an early stage of osteonecrosis without bone exposure. Likewise, follow-up images can indicate the onset of MRONJ with the presence of a heterogeneous bone pattern, persistence of the alveolar socket, a crater-like defect, and bone sequestrum. Moreover, when the high-risk local factors are recognized, a treatment plan that involves a closer follow-up after tooth extraction(s), the use of prophylactic antibiotics, antiseptic mouthwash, and L-PRF for MRONJ prevention, are recommended. As a word of caution, we suggest careful interpretation of our results, as the purpose of the univariate and multifactorial statistical analysis was to identify variables (or combinations of) that have a relationship with the development of osteonecrosis, rather than to establish causality. Further prospective studies are necessary to confirm the present findings.

Conclusion

Osteonecrosis may be anticipated upon recognition of the following associations described in the present study: teeth with absent and incomplete endodontic fillings with caries, widened periodontal ligament space and/or periapical lesions, and a sclerotic and heterogeneous preoperative alveolar bone pattern, in patients with longer ARD treatments. Most findings highlight the relevance of local infectious factors in the development of this pathology. Early identification of these features encourages a patient-specific decision making to take preventive measures during the treatment, giving importance to the quality of the conservative treatment and chronic dental infections in sites needing extraction in oncologic patients under ARD treatment.

https://doi.org/10.1038/s41598-022-15254-y
References

1. Campisi, G. et al. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 10, 237–275 (2014).

2. D’Oronzo, S., Coleman, R., Brown, J. & Silvestris, F. Metastatic bone disease: Pathogenesis and therapeutic options. J. Bone Oncol. 15, 100205 (2019).

3. Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243s–6249s (2006).

4. Gevárd, C., Bagán, J. V., Gevárd, C. & Bagán, J. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws: a review of the literature. Med. Oral Patol. Oral Cir. Bucal 21, e2270–e2276 (2016).

5. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J. Oral Maxillofac. Surg. 67, 2–12 (2009).

6. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 72, 1938–1956 (2014).

7. Schiødt, M. et al. Workshop of European task force on medication-related osteonecrosis of the jaw-current challenges. Oral Dis. 25, 1815–1821 (2019).

8. Otto, S., Pautke, C., Van den Wyngaert, T., Niepel, D. & Schiedt, M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat. Rev. 69, 177–187 (2018).

9. Taylor, K. H. H., Middlefell, L. S. S. & Mizen, K. D. D. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br. J. Oral Maxillofac. Surg. 48, 221–233 (2010).

10. Nicolatou-Galitis, O. et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 26, 955–966 (2020).

11. Gaêta-Araujo, H. et al. Why do some extraction sites develop medication-related osteonecrosis of the jaw and others do not? A within-patient study assessing radiographic predictors. Int. J. Oral Implantol. (Bari, Ger.) 14, 87–98 (2021).

12. Cardoso, C. L. et al. Radiographic findings in patients with medication-related osteonecrosis of the jaw. Int. J. Dent. 2017, 1–6 (2017).

13. Vandenbroucke, J. P. et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Int. J. Surg. 12, 1500–1524 (2014).

14. Viera, A. J. & Garrett, J. M. Understanding interobserver agreement: the kappa statistic. Fam. Med. 37, 360–363 (2005).

15. Moreno-Rabí, C., Gaêta-Araujo, H., Oliveira-Santos, C., Politis, C. & Jacobs, R. Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review. Clin. Oral Investig. 24, 2973–2989 (2020).

16. Ueda, N. et al. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer. J. Bone Miner. Metab. 39, 623–630 (2021).

17. Dimopoulos, M. A. et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 20, 117–120 (2009).

18. Ripamonti, C. et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 20, 137–145 (2009).

19. Klingerhöfler, C., Klingerhöfler, M., Müller, S., Ettl, T. & Wahllmann, U. Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw? Dentomaxillofac. Radiol. 45, 20160065 (2016).

20. Guo, Y., Wang, D., Wang, Y., Peng, X. & Guo, C. Imaging features of medicine-related osteonecrosis of the jaws: comparison between panoramic radiography and computed tomography. Oral Surg. Med. Oral Pathol. Oral Radiol. 122, e69–e76 (2016).

21. Ohbayo, J. et al. Bisphosphonate-related osteonecrosis of the jaw bone: radiological pattern and the potential role of CBCT in early diagnosis. J. Oral Maxillofac. Res. 1, e3 (2010).

22. Querrier, R. et al. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review. Support Care Cancer 29, 2811–2820 (2021).

23. Bedogni, A. et al. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bone disease. Br. J. Oral Maxillofac. Surg. 52, 603–608 (2014).

24. Bedogni, A., Fusco, V., Agraño, A. & Campisi, G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 18, 43–50 (2012).

25. Hamada, H., Matsuo, A., Koizumi, T., Satomi, T. & Chikazu, D. A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. J. Cranio-Maxillofac. Surg. 42, 924–929 (2014).

26. Torres, S. R. et al. Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates. Oral Surg. Med. Oral Pathol. Oral Radiol. 119, 584–92 (2015).

27. Aghaloo, T. L., Dry, S. M., Mallya, S. & Tetradis, S. Stage 0 osteonecrosis of the jaw in a patient on denosumab. J. Oral Maxillofac. Surg. 72, 702–716 (2014).

28. Şahin, O. et al. Comparison of findings of radiographic and fractal dimension analyses on panoramic radiographs of patients with early-stage and advanced-stage medication-related osteonecrosis of the jaw. Oral Surg. Med. Oral Pathol. Oral Radiol. 128, 78–86 (2019).

29. Hutchinson, M. et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J. Oral Maxillofac. Surg. 68, 2232–2240 (2010).

30. Ueda, N. et al. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents? Clin. Oral Investig. 25, 3087–3093 (2021).

31. Fedele, S. et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am. J. Med. 123, 1060–1064 (2010).

32. Arce, K., Assael, L. A., Weissman, J. L. & Markiewicz, M. R. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J. Oral Maxillofac. Surg. 67, 75–84 (2009).

33. Ruggiero, S. et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J. Oncol. Pract. 2, 7–14 (2006).

34. de Chevigny, C. et al. Treatment outcome in endodontics: the Toronto study—phase 4: initial treatment. J. Endod. 34, 258–263 (2008).

35. Koth, V. S., Figueiredo, M. A., Salum, F. G. & Cherubini, K. Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy. Dentomaxillofac. Radiol. 46, 20160260 (2017).

36. Matsuo, A. et al. Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Acta Odontol. Scand. 72, 656–663 (2014).

37. Nicolatou-Galitis, O. et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg. Med. Oral Pathol. Oral Radiol. 127, 117–135 (2019).
38. Van den Wyngaert, T. et al. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. Support. Care Cancer 21, 3483–3490 (2013).
39. Şahin, Ö., Tatar, B., Ekmeckioglu, C., Aliyev, T. & Odabaşı, O. Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: an institution’s experience. J. Clin. Exp. Dent. 12, e771–e776 (2020).
40. Spanou, A. et al. Primary wound closure and perioperative antibiotic therapy for prevention of bisphosphonate-related osteonecrosis of the jaw after tooth extraction. Quintessence Int. 51, 220–228 (2020).
41. Pippi, R., Giuliani, U., Tenore, G., Pietrantoni, A. & Romeo, U. What is the risk of developing medication-related osteonecrosis in patients with extraction sockets left to heal by secondary intention? A retrospective case series study. J. Oral Maxillofac. Surg. 79, 2071–2077 (2021).
42. Miranda, M. et al. The role of platelet-rich fibrin (PRF) in the prevention of medication-related osteonecrosis of the jaw (MRONJ). Biomed Res. Int. 2021, 1–8 (2021).
43. Asaka, T. et al. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin. Oral Investig. 21, 2165–2172 (2017).

Author contributions
C.M.R.: conceptualization, methodology, investigation, writing—original draft, writing—review and editing. L.L.: investigation, writing—original draft, writing—review and editing. H.G.A.: investigation, writing—original draft, writing—review and editing. A.L.: writing—investigation, writing—original draft, writing—review and editing. W.C.: statistical analysis. T.V.D.W.: writing—review and editing, supervision. R.J.: conceptualization, writing—review and editing, supervision.

Funding
Open access funding provided by Karolinska Institute.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to R.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022